Parallax Volatility Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,300
| Closed | -$1M | – | 1779 |
|
|
2025
Q4 | $1M | Buy |
+1,300
| New | +$883K | ﹤0.01% | 1116 |
|
|
2025
Q2 | – | Sell |
-17,000
| Closed | -$10.8M | – | 1771 |
|
|
2025
Q1 | $10.8M | Buy |
17,000
+7,600
| +81% | +$5.23M | 0.03% | 437 |
|
|
2024
Q4 | $6.7M | Sell |
9,400
-100
| -1% | -$83.9K | 0.01% | 718 |
|
|
2024
Q3 | $9.99M | Sell |
9,500
-600
| -6% | -$668K | 0.02% | 549 |
|
|
2024
Q2 | $10.6M | Sell |
10,100
-12,500
| -55% | -$12.1M | 0.02% | 461 |
|
|
2024
Q1 | $21.8M | Sell |
22,600
-16,600
| -42% | -$15.8M | 0.05% | 298 |
|
|
2023
Q4 | $34.4M | Sell |
39,200
-12,300
| -24% | -$10.1M | 0.07% | 255 |
|
|
2023
Q3 | $42.4M | Buy |
51,500
+41,400
| +410% | +$32.5M | 0.09% | 173 |
|
|
2023
Q2 | $7.26M | Buy |
10,100
+200
| +2% | +$154K | 0.02% | 635 |
|
|
2023
Q1 | $8.13M | Sell |
9,900
-13,100
| -57% | -$9.88M | 0.02% | 660 |
|
|
2022
Q4 | $16.6M | Sell |
23,000
-7,900
| -26% | -$5.83M | 0.03% | 583 |
|
|
2022
Q3 | $21.3M | Buy |
30,900
+17,500
| +131% | +$11M | 0.03% | 506 |
|
|
2022
Q2 | $7.92M | Buy |
+13,400
| New | +$8.71M | 0.01% | 814 |
|
|
2022
Q1 | – | Sell |
-21,500
| Closed | -$13.6M | – | 3102 |
|
|
2021
Q4 | $13.6M | Buy |
21,500
+8,500
| +65% | +$5.23M | 0.02% | 512 |
|
|
2021
Q3 | $7.87M | Buy |
+13,000
| New | +$8.07M | 0.01% | 726 |
|
|
2021
Q1 | – | Sell |
-35,900
| Closed | -$17.3M | – | 2039 |
|
|
2020
Q4 | $17.3M | Buy |
35,900
+24,200
| +207% | +$13.1M | 0.02% | 564 |
|
|
2020
Q3 | $6.55M | Buy |
+11,700
| New | +$7.09M | ﹤0.01% | 1180 |
|
|
2020
Q2 | – | Sell |
-300
| Closed | -$146K | – | 2844 |
|
|
2020
Q1 | $146K | Sell |
300
-36,000
| -99% | -$14.8M | ﹤0.01% | 2053 |
|
|
2019
Q4 | $13.6M | Buy |
36,300
+35,000
| +2,692% | +$11.8M | 0.02% | 545 |
|
|
2019
Q3 | $360K | Sell |
1,300
-79,100
| -98% | -$23.4M | ﹤0.01% | 1704 |
|
|
2019
Q2 | $25.2M | Buy |
80,400
+66,400
| +474% | +$22.1M | 0.03% | 293 |
|
|
2019
Q1 | $5.75M | Sell |
14,000
-65,300
| -82% | -$26.9M | 0.01% | 651 |
|
|
2018
Q4 | $29.6M | Buy |
79,300
+19,700
| +33% | +$7.21M | 0.04% | 274 |
|
|
2018
Q3 | $24.1M | Buy |
59,600
+1,600
| +3% | +$609K | 0.03% | 247 |
|
|
2018
Q2 | $20M | Buy |
58,000
+33,000
| +132% | +$10.3M | 0.03% | 269 |
|
|
2018
Q1 | $8.61M | Buy |
25,000
+13,000
| +108% | +$4.52M | 0.01% | 413 |
|
|
2017
Q4 | $4.51M | Sell |
12,000
-1,000
| -8% | -$405K | 0.01% | 640 |
|
|
2017
Q3 | $5.81M | Buy |
13,000
+5,000
| +63% | +$2.38M | 0.01% | 531 |
|
|
2017
Q2 | $3.93M | Sell |
8,000
-56,500
| -88% | -$24.7M | 0.01% | 634 |
|
|
2017
Q1 | $25M | Buy |
64,500
+39,500
| +158% | +$14.6M | 0.05% | 208 |
|
|
2016
Q4 | $9.18M | Hold |
25,000
| – | – | 0.02% | 464 |
|
|
2016
Q3 | $10.1M | Hold |
25,000
| – | – | 0.02% | 433 |
|
|
2016
Q2 | $8.73M | Hold |
25,000
| – | – | 0.02% | 458 |
|
|
2016
Q1 | $9.01M | Hold |
25,000
| – | – | 0.02% | 391 |
|
|
2015
Q4 | $13.6M | Hold |
25,000
| – | – | 0.03% | 367 |
|
|
2015
Q3 | $11.6M | Hold |
25,000
| – | – | 0.03% | 388 |
|
|
2015
Q2 | $12.8M | Hold |
25,000
| – | – | 0.03% | 417 |
|
|
2015
Q1 | $11.3M | Buy |
+25,000
| New | +$10.6M | 0.03% | 436 |
|
|
2014
Q2 | – | Sell |
-43,500
| Closed | -$13.1M | – | 4262 |
|
|
2014
Q1 | $13.1M | Buy |
+43,500
| New | +$13.4M | 0.08% | 206 |
|
Other funds holding REGN
VCM
N
Parallax Volatility Advisers's REGN Position: Q1 2026 in Review
Parallax Volatility Advisers sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 321 shares — an estimated $248K sold.
Parallax Volatility Advisers first reported a position in REGN in Q1 2014 and held it in 37 quarters. The position peaked at $18M in Q4 2018. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Parallax Volatility Advisers reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Parallax Volatility Advisers sold 321 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $248K.
- Parallax Volatility Advisers first reported a position in Regeneron Pharmaceuticals in Q1 2014 and held it in 37 quarters.
- Parallax Volatility Advisers's Regeneron Pharmaceuticals position peaked at $18M in Q4 2018.
- 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.